相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer
Eleftherios P. Mamounas
ANNALS OF SURGICAL ONCOLOGY (2015)
Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
Koen van de Ven et al.
IMMUNOTHERAPY (2015)
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
G. G. Steger et al.
ANNALS OF ONCOLOGY (2014)
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
Alfredo Berruti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
Chiharu Tabata et al.
BMC CANCER (2013)
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer
Tobias Arnold et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
Yvonne Nadine Fahmueller et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression
Samuel T. Haile et al.
JOURNAL OF IMMUNOLOGY (2013)
HMGB1 Levels Are Increased in Patients with Juvenile Idiopathic Arthritis, Correlate with Early Onset of Disease, and Are Independent of Disease Duration
Hanna Schierbeck et al.
JOURNAL OF RHEUMATOLOGY (2013)
PDZK1 Is a Novel Factor in Breast Cancer That Is Indirectly Regulated by Estrogen through IGF-1R and Promotes Estrogen-Mediated Growth
Hogyoung Kim et al.
MOLECULAR MEDICINE (2013)
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
Oliver J. Stoetzer et al.
TUMOR BIOLOGY (2013)
被撤回的出版物: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity (Publication with Expression of Concern. See vol. 73, pg. 1297, 2020) (Publication with Expression of Concern. See vol. 69, pg. 1402, 2018) (Retracted article. See vol. 73, pg. 1297, 2020)
Daniel J. Antoine et al.
JOURNAL OF HEPATOLOGY (2012)
A Janus Tale of Two Active High Mobility Group Box 1 (HMGB1) Redox States
Daolin Tang et al.
MOLECULAR MEDICINE (2012)
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
Naoe Goto et al.
LEUKEMIA & LYMPHOMA (2012)
Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy
Nikolaus Kohles et al.
TUMOR BIOLOGY (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Circulating apoptotic and necrotic cell death markers in patients with acute liver injury
Darren G. N. Craig et al.
LIVER INTERNATIONAL (2011)
High-mobility group box 1 and cancer
Daolin Tang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2
Silke Huber et al.
BLOOD (2010)
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel et al.
CLINICAL CANCER RESEARCH (2010)
Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology
Martijn A. Nolte et al.
IMMUNOLOGICAL REVIEWS (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Alfredo Berruti et al.
ONCOLOGIST (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Molecular characteristics of immunogenic cancer cell death
A. Tesniere et al.
CELL DEATH AND DIFFERENTIATION (2008)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Human soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation
M. Kakoulidou et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2007)
Systemic inflammation and remote organ injury following trauma require HMGB1
Ryan M. Levy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Clearance of apoptotic and necrotic cells and its immunological consequences
Dmitri V. Krysko et al.
APOPTOSIS (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-mobility group box 1 protein (HMGB): Nuclear weapon in the immune arsenal
MT Lotze et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock
J Sundén-Cullberg et al.
CRITICAL CARE MEDICINE (2005)
Cloning and identification of two novel splice variants of human PD-L2
XH He et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2004)
分享论文
